Recerca

Àrea 1

Malalties infeccioses i SIDA

Factor d'impacte: mitjana: 4.86, total: 398.78

Articles de l'any 2010
Original
  • Long-Term Efficacy and Safety of Raltegravir Combined with Optimized Background Therapy in Treatment-Experienced Patients with Drug-Resistant HIV Infection: Week 96 Results of the BENCHMRK 1 and 2 Phase III Trials

    Steigbigel RT, Cooper DA, Teppler H, Eron JJ, Gatell JM, Kumar PN, Rockstroh JK, Schechter M, Katlama C, Markowitz M, Yeni P, Loutfy MR, Lazzarin A, Lennox JL, Clotet B, Zhao J, Wan H, Rhodes RR, Strohmaier KM, Barnard RJ, Isaacs RD, Nguyen BYT
    CLIN INFECT DIS. 2010; 50: 605-612. IF: 8.195

  • Validation of the American Thoracic Society-Infectious Diseases Society of America Guidelines for Hospital-Acquired Pneumonia in the Intensive Care Unit

    Ferrer M, Liapikou A, Valencia M, Esperatti M, Theessen A, Martinez JA, Mensa J, Torres A
    CLIN INFECT DIS. 2010; 50: 945-952. IF: 8.195

  • Phenotype and functional analysis of human monocytes-derived dendritic cells loaded with a carbosilane dendrimer

    Pion M, Serramia MJ, Diaz L, Bryszewska M, Gallart T, Garcia F, Gomez R, DeLaMata FJ, Munoz-Fernandez MA
    BIOMATERIALS. 2010; 31: 8749-8758. IF: 7.365

  • Nursing home-acquired pneumonia: a 10 year single-centre experience

    Polverino E, Dambrava P, Cilloniz C, Balasso V, Marcos MA, Esquinas C, Mensa J, Ewig S, Torres A
    THORAX. 2010; 65: 354-359. IF: 7.041

  • Selective Induction of Host Genes by MVA-B, a Candidate Vaccine against HIV/AIDS

    Guerra S, Gonzalez JM, Climent N, Reyburn H, Lopez-Fernandez LA, Najera JL, Gomez CE, Garcia F, Gatell JM, Gallart T, Esteban M
    J VIROL. 2010; 84: 8141-8152. IF: 5.15

  • Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients

    Mocroft A, Kirk O, Reiss P, DeWit S, Sedlacek D, Beniowski M, Gatell J, Phillips AN, Ledergerber B, Lundgren JD
    AIDS. 2010; 24: 1667-1678. IF: 4.909

  • Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study

    Martinez E, Larrousse M, Llibre JM, Gutierrez F, Saumoy M, Antela A, Knobel H, Murillas J, Berenguer J, Pich J, Perez I, Gatell JM
    AIDS. 2010; 24: 1697-1707. IF: 4.909

  • Abacavir-based therapy does not affect biological mechanisms associated with cardiovascular dysfunction

    Martinez E, Larrousse M, Podzamczer D, Perez I, Gutierrez F, Lonca M, Barragan P, Deulofeu R, Casamitjana R, Mallolas J, Pich J, Gatell JM
    AIDS. 2010; 24: 0-0. IF: 4.909

  • The effects of intermittent, CD4-guided antiretroviral therapy on body composition and metabolic parameters

    Martinez E, Visnegarwala F, Grund B, Thomas A, Gibert C, Shlay J, Drummond F, Pearce D, Edwards S, Reiss P, El-Sadr W, Carr A
    AIDS. 2010; 24: 353-363. IF: 4.909

  • Etravirine resistance associated mutations in HIV-infected patients failing efavirenz or nevirapine in the Spanish antiretroviral resistance database

    Poveda E, Anta L, Blanco JL, Perez-Elias MJ, Garcia F, Leal M, Ribera E, Gutierrez F, Soriano V, DeMendoza C
    AIDS. 2010; 24: 469-471. IF: 4.909

  • Factors associated with collagen deposition in lymphoid tissue in long-term treated HIV-infected patients

    Diaz A, Alos L, Leon A, Mozos A, Caballero M, Martinez A, Plana M, Gallart T, Gil C, Leal M, Gatell JM, Garcia F
    AIDS. 2010; 24: 2029-2039. IF: 4.909

  • The MMP1 (-16071G/2G) single nucleotide polymorphism associates with the HAART-related lipodystrophic syndrome

    Montes AH, Valle-Garay E, Suarez-Zarracina T, Melon S, Martinez E, Carton JA, Collazos J, Asensi V
    AIDS. 2010; 24: 2495-2502. IF: 4.909

  • Daptomycin Is Effective for Treatment of Experimental Endocarditis Due to Methicillin-Resistant and Glycopeptide-Intermediate Staphylococcus epidermidis

    Garcia-De-La-Maria C, Marco F, Armero Y, Soy D, Moreno A, DelRio A, Almela M, Cervera C, Ninot S, Falces C, Mestres CA, Gatell JM, DeAnta MTJ, Miro JM
    ANTIMICROB AGENTS CH. 2010; 54: 2781-2786. IF: 4.802

  • Drug Resistance Mutations in HIV-Infected Patients in the Spanish Drug Resistance Database Failing Tipranavir and Darunavir Therapy

    Poveda E, Anta L, Blanco JL, Casado JL, Gutierrez F, Garcia F, Gomez-Sirvent JL, Iribarren JA, Soriano V, DeMendoza C
    ANTIMICROB AGENTS CH. 2010; 54: 3018-3020. IF: 4.802

  • Effect of Synthetic Peptides Belonging to E2 Envelope Protein of GB Virus C on Human Immunodeficiency Virus Type 1 Infection

    Herrera E, Tenckhoff S, Gomara MJ, Galatola R, Bleda MJ, Gil C, Ercilla G, Gatell JM, Tillmann HL, Haro I
    J MED CHEM. 2010; 53: 6054-6063. IF: 4.802

  • Influence of Empiric Therapy with a beta-Lactam Alone or Combined with an Aminoglycoside on Prognosis of Bacteremia Due to Gram-Negative Microorganisms

    Martinez JA, Cobos-Trigueros N, Soriano A, Almela M, Ortega M, Marco F, Pitart C, Sterzik H, Lopez J, Mensa J
    ANTIMICROB AGENTS CH. 2010; 54: 3590-3596. IF: 4.802

  • When and why to start antiretroviral therapy?

    Gatell JM
    J ANTIMICROB CHEMOTH. 2010; 65: 383-385. IF: 4.352

  • Candida spp. bloodstream infection: influence of antifungal treatment on outcome

    Ortega M, Marco F, Soriano A, Almela M, Martinez JA, Pitart C, Mensa J
    J ANTIMICROB CHEMOTH. 2010; 65: 562-568. IF: 4.352

  • Increased alpha-Defensins 1-3 Production by Dendritic Cells in HIV-Infected Individuals Is Associated with Slower Disease Progression

    Rodriguez-Garcia M, Climent N, Oliva H, Casanova V, Franco R, Leon A, Gatell JM, Garcia F, Gallart T
    PLOS ONE. 2010; 5: 0-0. IF: 4.351

  • Activation of the EGFR/ERK pathway in high-grade mucoepidermoid carcinomas of the salivary glands

    Lujan B, Hakim S, Moyano S, Nadal A, Caballero M, Diaz A, Valera A, Carrera M, Cardesa A, Alos L
    BRIT J CANCER. 2010; 103: 510-516. IF: 4.346

  • Dialysis and Renal Transplantation in HIV-Infected Patients: a European Survey

    Trullas JC, Mocroft A, Cofan F, Tourret J, Moreno A, Bagnis CI, Fux CA, Katlama C, Reiss P, Lundgren J, Gatell JM, Kirk O, Miro JM
    JAIDS-J ACQ IMM DEF. 2010; 55: 582-589. IF: 4.207

  • Long-Term Efficacy and Safety of the HIV Integrase Inhibitor Raltegravir in Patients With Limited Treatment Options in a Phase II Study

    Gatell JM, Katlama C, Grinsztejn B, Eron JJ, Lazzarin A, Vittecoq D, Gonzalez CJ, Danovich RM, Wan H, Zhao J, Meibohm AR, Strohmaier KM, Harvey CM, Isaacs RD, Nguyen BYT
    JAIDS-J ACQ IMM DEF. 2010; 53: 456-463. IF: 4.207

  • Serious Fatal and Nonfatal Non-AIDS-Defining Illnesses in Europe

    Mocroft A, Reiss P, Gasiorowski J, Ledergerber B, Kowalska J, Chiesi A, Gatell J, Rakhmanova A, Johnson M, Kirk O, Lundgren J
    JAIDS-J ACQ IMM DEF. 2010; 55: 262-270. IF: 4.207

  • Predictors of Immune Reconstitution Inflammatory Syndrome-Associated With Kaposi Sarcoma in Mozambique: A Prospective Study

    Letang E, Almeida JM, Miro JM, Ayala E, White IE, Carrilho C, Bastos R, Nhampossa T, Menendez C, Campbell TB, Alonso PL, Naniche D
    JAIDS-J ACQ IMM DEF. 2010; 53: 589-597. IF: 4.207

  • Predictors of candidaemia caused by non-albicans Candida species: results of a population-based surveillance in Barcelona, Spain

    Rodriguez D, Almirante B, Cuenca-Estrella M, Rodriguez-Tudela JL, Mensa J, Ayats J, Sanchez F, Pahissa A
    CLIN MICROBIOL INFEC. 2010; 16: 1676-1682. IF: 4.014

  • Differential HMG-CoA lyase expression in human tissues provides clues about 3-hydroxy-3-methylglutaric aciduria

    Puisac B, Arnedo M, Casale CH, Ribate MP, Castiella T, Ramos FJ, Ribes A, Perez-Cerda C, Casals N, Hegardt FG, Pie J
    J INHERIT METAB DIS. 2010; 33: 405-410. IF: 3.598

  • Pilot Study Assessing HIV Vaccine Trial Readiness Among Female Sex Workers, Injection and Non-injection Drug Users, and Men Who Have Sex with Men in Spain

    Etcheverry MF, DeLazzari E, Fuchs JD, Merono M, Sierra E, DelRomero J, Evans JL, Mendez-Arancibia E, Jacques C, Rojas D, Segu M, Gatell JM, Joseph J
    AIDS BEHAV. 2010; 14: 607-617. IF: 3.038

  • HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects

    Buzon MJ, Massanella M, Llibre JM, Esteve A, Dahl V, Puertas MC, Gatell JM, Domingo P, Paredes R, Sharkey M, Palmer S, Stevenson M, Clotet B, Blanco J, Martinez-Picado J
    NAT MED. 2010; 16: 460-0. IF: 27.136

  • Effects of highly active antiretroviral therapy on vaccine-induced humoral immunity in HIV-infected adults

    Gonzalez R, Castro P, Garcia F, Plana M, Bayas JM, Lafuente S, Serrano B, Mora B, Argelich R, Gatell JM, Vilella A
    HIV MED. 2010; 11: 535-539. IF: 2.878

  • Effect of TNF-a genetic variants and CCR5 Delta 32 on the vulnerability to HIV-1 infection and disease progression in Caucasian Spaniards

    Veloso S, Olona M, Garcia F, Domingo P, Alonso-Villaverde C, Broch M, Peraire J, Vilades C, Plana M, Pedrol E, Lopez-Dupla M, Aguilar C, Gutierrez M, Leon A, Tasias M, Gatell JM, Richart C, Vidal F
    BMC MED GENET. 2010; 11: 63-63. IF: 2.84

  • Prevalence of dihydropteroate synthase genotypes before and after the introduction of combined antiretroviral therapy and their influence on the outcome of Pneumocystis pneumonia in HIV-1-infected patients

    Alvarez-Martinez MJ, Miro JM, Valls ME, Mas J, DeLaBellacasa JP, Sued O, Sole M, Rivas PV, DeLazzari E, Benito N, Garcia F, Agusti C, Wilson PE, Gatell JM, DeAnta MTJ, Meshnick SR, Moreno A
    DIAGN MICR INFEC DIS. 2010; 68: 60-65. IF: 2.451

  • Fat Mass Ratio: An Objective Tool to Define Lipodystrophy in HIV-Infected Patients Under Antiretroviral Therapy

    Freitas P, Santos AC, Carvalho D, Pereira J, Marques R, Martinez E, Sarmento A, Medina JL
    J CLIN DENSITOM. 2010; 13: 197-203. IF: 2.389

  • Prevalence of enterotoxins among Escherichia coli isolates causing bacteraemia

    Telli M, Guiral E, Martinez JA, Almela M, Bosch J, Vila J, Soto SM
    FEMS MICROBIOL LETT. 2010; 306: 117-121. IF: 2.199

  • Immune Reconstitution in Severely Immunosuppressed Antiretroviral-Naive HIV Type 1-Infected Patients Using a Nonnucleoside Reverse Transcriptase Inhibitor-Based or a Boosted Protease Inhibitor-Based Antiretroviral Regimen: Three-Year Results

    Miro JM, Manzardo C, Pich J, Domingo P, Ferrer E, Arribas JR, Ribera E, Arrizabalaga J, Lonca M, Cruceta A, DeLazzari E, Fuster M, Podzamczer D, Plana M, Gatell JM
    AIDS RES HUM RETROV. 2010; 26: 747-757. IF: 2.178

  • Immunosuppressive therapy and infection after kidney transplantation

    Fortun J, Martin-Davila P, Pascual J, Cervera C, Moreno A, Gavalda J, Aguado JM, Pereira P, Gurgui M, Carratala J, Fogueda M, Montejo M, Blasco F, Bou G, Torre-Cisneros J
    TRANSPL INFECT DIS. 2010; 12: 397-405. IF: 2.063

  • Analysis of the Impact of Early Surgery on In-Hospital Mortality of Native Valve Endocarditis Use of Propensity Score and Instrumental Variable Methods to Adjust for Treatment-Selection Bias

    Lalani T, Cabell CH, Benjamin DK, Lasca O, Naber C, Fowler VG, Corey GR, Chu VH, Fenely M, Pachirat O, Tan RS, Watkin R, Ionac A, Moreno A, Mestres CA, Casabe J, Chipigina N, Eisen DP, Spelman D, Delahaye F, Peterson G, Olaison L, Wang A
    CIRCULATION. 2010; 121: 1005-1013. IF: 14.816

  • Molecular Characterization of Heterologous HIV-1gp120 Gene Expression Disruption in Mycobacterium bovis BCG Host Strain: A Critical Issue for Engineering Mycobacterial Based-Vaccine Vectors

    Joseph J, Fernandez-Lloris R, Pezzat E, Saubi N, Cardona PJ, Mothe B, Gatell JM
    J BIOMED BIOTECHNOL. 2010; 0: 0-0. IF: 1.75

  • Development of Diagnostic Criteria for Serious Non-AIDS Events in HIV Clinical Trials

    Lifson AR, Belloso WH, Davey RT, Duprez D, Gatell JM, Hoy JF, Krum EA, Nelson R, Pedersen C, Perez G, Price RW, Prineas RJ, Rhame FS, Sampson JH, Worley J
    HIV CLIN TRIALS. 2010; 11: 205-219. IF: 1.626

  • Predicting bacteremic pneumonia in HIV-1-infected patients consulting the ED

    Perello R, Miro O, Marcos MA, Almela M, Bragulat E, Sanchez M, Agusti C, Miro JM, Moreno A
    AM J EMERG MED. 2010; 28: 454-459. IF: 1.542

  • Characteristics of antiviral drugs, excluding antiretroviral agents: Update 2009

    Tuset M, Lopez-Sune E, Cervera C, Moreno A, Miro JM
    ENFERM INFEC MICR CL. 2010; 28: 199-199. IF: 1.393

  • Characteristics of hepatitis and influenza antivirals: update 2009

    Lopez-Sune E, Tuset M, Laguno M, Moreno A, Miro JM
    ENFERM INFEC MICR CL. 2010; 28: 253-253. IF: 1.393

  • Daptomycin compared to standard therapy for the treatment of native valve endocarditis

    Kanafani Z, Boucher H, Fowler V, Cabell C, Hoen B, Miro JM, Lalani T, Vigliani G, Campion M, Corey R, Levine D
    ENFERM INFEC MICR CL. 2010; 28: 498-503. IF: 1.393

  • On the way to shortening tuberculosis treatments: clinical trials of the Unitat d' Investagacio en Tuberculosi de Barcelona supported by the Centers for Disease Control and Prevention

    Moreno A, Sanchez F, Nelson J, Miro JM, Cayla JA
    GAC SANIT. 2010; 24: 171-171. IF: 1.172

  • Community-Acquired Methicillin-Resistant Staphylococcus aureus Meningitis Complicated by Cerebral Infarction. Role of Antibiotic Combination of Linezolid Plus Levofloxacin

    Fernandez-Ruiz M, Cervera C, Pitart C, Perez G, DelRio A, Miro JM, Marco F, Moreno A
    INTERNAL MED. 2010; 49: 1971-1974. IF: 1.04

  • Epidemiology of Pneumonia in Kidney Transplantation

    Hoyo I, Linares L, Cervera C, Almela M, Marcos MA, Sanclemente G, Cofan F, Ricart MJ, Moreno A
    TRANSPL P. 2010; 42: 2938-2940. IF: 0.994

  • Klebsiella pneumoniae Infection in Solid Organ Transplant Recipients: Epidemiology and Antibiotic Resistance

    Linares L, Cervera C, Hoyo I, Sanclemente G, Marco F, Cofan F, Ricart MJ, Navasa M, Moreno A
    TRANSPL P. 2010; 42: 2941-2943. IF: 0.994

  • Epidemiology and clinical presentation of Panton-Valentine leukocidin positive methicillin-resistant Staphylococcus aureus

    Cobos-Trigueros N, Pitart C, Marco F, Martinez JA, Almela M, Lopez J, Ortega M, Soriano A, Mensa J
    REV ESP QUIM. 2010; 23: 93-99. IF: 0.725

Revisió
  • Role of fixed-dose combinations of antiretrovirals in HIV-1 therapy

    Llibre JM, Antela A, Arribas JR, Domingo P, Gatell JM, Lopez-Aldeguer J, Lozano F, Miralles C, Molto J, Moreno S, Ortega E, Riera M, Rivero A, Villalonga C, Clotet B
    ENFERM INFEC MICR CL. 2010; 28: 615-620. IF: 1.393

  • Antifungal prophylaxis in oncohematologic patients: Literature review and recommendations

    DeLaCamara R, Mensa J, Carreras E, Estrella MC, Rodriguez JAG, Gobernado M, Picazo J, Aguado JM, Sanz MA
    MED CLIN-BARCELONA. 2010; 134: 222-233. IF: 1.231

  • Simultaneous Pancreas-Kidney Transplantation in HIV-infected Patients: A Case Report and Literature Review

    Miro JM, Ricart MJ, Trullas JC, Cofan F, Cervera C, Brunet M, Tuset M, Manzardo C, Oppenheimer F, Moreno A
    TRANSPL P. 2010; 42: 3887-3891. IF: 0.994

  • Endotoxin adsortion as adjuvant therapy in gramnegative severe sepsis

    Candel FJ, Martinez-Sagasti F, Borges M, Maseda E, Herrera-Gutierrez M, Garnacho-Montero J, Maynar FJ, Zaragoza R, Mensa J, Azanza JR
    REV ESP QUIM. 2010; 23: 115-121. IF: 0.725

Editorials
  • How to promote and facilitate the early diagnosis of HIV-1 infection: the emergency department's role

    Gatell JM, Zulaica D, DelRomero J, Robledo T
    EMERGENCIAS. 2010; 22: 230-232. IF: 3.08

Multicèntrics
  • Triple-Class Virologic Failure in HIV-Infected Patients Undergoing Antiretroviral Therapy for Up to 10 Years

    Lodwick R, Costagliola D, Reiss P, Torti C, Teira R, Dorrucci M, Ledergerber B, Mocroft A, Podzamczer D, Cozzi-Lepri A, Obel N, Masquelier B, Staszewski S, Garcia F, DeWit S, Castagna A, Antinori A, Judd A, Ghosn J, Touloumi G, Mussini C, Duval X, Ramos J, Meyer L, Warsawski J, Thorne C, Masip J, Perez-Hoyos S, Pillay D, VanSighem A, LoCaputo S, Gunthard H, Paredes R, DeLuca A, Paraskevis D, Fabre-Colin C, Kjaer J, Chene G, Lundgren JD, Phillips AN
    ARCH INTERN MED. 2010; 170: 410-419. IF: 9.813

  • Modelling the Evolution and Spread of HIV Immune Escape Mutants

    Fryer HR, Frater J, Duda A, Roberts MG, Phillips RE, Mclean AR
    PLOS PATHOG. 2010; 6: 0-0. IF: 8.978

  • Kaposi Sarcoma (KS)-Associated Herpesvirus MicroRNA Sequence Analysis and KS Risk in a European AIDS-KS Case Control Study

    Marshall V, Martro E, Labo N, Ray A, Wang DA, Mbisa G, Bagni RK, Volfovsky N, Casabona J, Whitby D
    J INFECT DIS. 2010; 202: 1126-1135. IF: 5.865

  • Risk of Myocardial Infarction in Patients with HIV Infection Exposed to Specific Individual Antiretroviral Drugs from the 3 Major Drug Classes: The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study

    Worm SW, Sabin C, Weber R, Reiss P, El-Sadr W, Dabis F, DeWit S, Law M, Monforte AD, Friis-Moller N, Kirk O, Fontas E, Weller I, Phillips A, Lundgren J
    J INFECT DIS. 2010; 201: 318-330. IF: 5.865

  • Relationship Between Current Level of Immunodeficiency and Non-Acquired Immunodeficiency Syndrome-Defining Malignancies

    Reekie J, Kosa C, Engsig F, Monforte AD, Wiercinska-Drapalo A, Domingo P, Antunes F, Clumeck N, Kirk O, Lundgren JD, Mocroft A
    CANCER-AM CANCER SOC. 2010; 116: 5306-5315. IF: 5.418

  • Frequent hepatitis B virus rebound among HIV-hepatitis B virus-coinfected patients following antiretroviral therapy interruption

    Dore GJ, Soriano V, Rockstroh J, Kupfer B, Tedaldi E, Peters L, Neuhaus J, Puoti M, Klein MB, Mocroft A, Clotet B, Lundgren JD
    AIDS. 2010; 24: 857-865. IF: 4.909

  • The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals

    Ray M, Logan R, Sterne JAC, Hernandez-Diaz S, Robins JM, Sabin C, Bansi L, VanSighem A, DeWolf F, Costagliola D, Lanoy E, Bucher HC, VonWyl V, Esteve A, Casabona J, DelAmo J, Moreno S, Justice A, Gouler J, Lodi S, Phillips A, Seng R, Meyer L, Perez-Hoyos S, DeOlalla PG, Herman MA, Phillips AN, Gilson R, Easterbrook P, Fisher M, Gazzard B, Johnson M, Walsh J, Leen C, Orkin C, Anderson J, Pillay D, Delpech V, Schwenk A, Dunn D, Gompels M, Hill T, Porter K, Babiker A
    AIDS. 2010; 24: 123-137. IF: 4.909

  • Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D study The Data Collection on Adverse Events of Anti-HIV drugs (D:A:D) Study Group

    Smith C, Sabin CA, Lundgren JD, Thiebaut R, Weber R, Law M, Monforte AD, Kirk O, Friis-Moller N, Phillips A, Reiss P, El-Sadr W, Pradier C, Worm SW
    AIDS. 2010; 24: 1537-1548. IF: 4.909

  • High prevalence of the metabolic syndrome in HIV-infected patients: impact of different definitions of the metabolic syndrome

    Worm SW, Friis-Moller N, Bruyand M, Monforte AD, Rickenbach M, Reiss P, El-Sadr W, Phillips A, Lundgren J, Sabin C
    AIDS. 2010; 24: 427-435. IF: 4.909

  • Predictors of hepatitis B virus genotype and viraemia in HIV-infected patients with chronic hepatitis B in Europe

    Soriano V, Mocroft A, Peters L, Rockstroh J, Antunes F, Kirkby N, DeWit S, Monforte AD, Flisiak R, Lundgren J
    J ANTIMICROB CHEMOTH. 2010; 65: 548-555. IF: 4.352

  • Influence of M. tuberculosis Lineage Variability within a Clinical Trial for Pulmonary Tuberculosis

    Nahid P, Bliven EE, Kim EY, MacKenzie WR, Stout JE, Diem L, Johnson JL, Gagneux S, Hopewell PC, Kato-Maeda M
    PLOS ONE. 2010; 5: 0-0. IF: 4.351

  • Effects of Intermittent IL-2 Alone or with Peri-Cycle Antiretroviral Therapy in Early HIV Infection: The STALWART Study

    Tavel JA
    PLOS ONE. 2010; 5: 0-0. IF: 4.351

  • HBV or HCV coinfections and risk of myocardial infarction in HIV-infected individuals: the D:A:D Cohort Study

    Weber R, Sabin C, Reiss P, DeWit S, Worm SW, Law M, Dabis F, Monforte AD, Fontas E, El-Sadr W, Kirk O, Rickenbach M, Phillips A, Ledergerber B, Lundgren J
    ANTIVIR THER. 2010; 15: 1077-1086. IF: 4.322

  • Estimated average annual rate of change of CD4(+) T-cell counts in patients on combination antiretroviral therapy

    Mocroft A, Phillips AN, Ledergerber B, Smith C, Bogner JR, Lacombe K, Wiercinska-Drapalos A, Reiss P, Kirk O, Lundgren JD
    ANTIVIR THER. 2010; 15: 563-570. IF: 4.322

  • Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per mu L in Europe and North America: a pooled cohort observational study

    Lodwick RK, Sabin CA, Porter K, Ledergerber B, VanSighem A, Cozzi-Lepri A, Khaykin P, Mocroft A, Jacobson L, DeWit S, Obel N, Castagna A, Wasmuth JC, Gill J, Klein MB, Gange S, Riera M, Mussini C, Gutierrez F, Touloumi G, Carrieri P, Guest JL, Brockmeyer NH, Phillips AN
    LANCET. 2010; 376: 340-345. IF: 30.758

  • History of viral suppression on combination antiretroviral therapy as a predictor of virological failure after a treatment change*

    Reekie J, Mocroft A, Ledergerber B, Beniowski M, Clotet B, VanLunzen J, Chiesi A, Pradier C, Machala L, Lundgren JD
    HIV MED. 2010; 11: 469-478. IF: 2.878

  • Predicting the risk of cardiovascular disease in HIV-infected patients: the Data collection on Adverse Effects of Anti-HIV Drugs Study

    Friis-Moller N, Thiebaut R, Reiss P, Weber R, Monforte AD, DeWit S, El-Sadr W, Fontas E, Worm S, Kirk O, Phillips A, Sabin CA, Lundgren JD, Law MG
    EUR J CARDIOV PREV R. 2010; 17: 491-501. IF: 2.511

  • Current situation of human immunodeficiency virus type 2 and Human T lymphotropic virus in Spain

    Trevino A, Soriano V
    ENFERM INFEC MICR CL. 2010; 28: 442-445. IF: 1.393

  • AIDS Study Group/Spanish AIDS Plan consensus document on antiretroviral therapy in adults with human immunodeficiency virus infection (updated January 2010)

    Aldeguer JL, Et AL
    ENFERM INFEC MICR CL. 2010; 28: 0-0. IF: 1.393

  • Diagnosis, treatment and prevention of renal diseases in HIV infected patients. Recommendations of the Spanish AIDS Study Group/National AIDS Plan28(8):520.e1-22

    Gutierrez F, Et AL
    ENFERM INFEC MICR CL. 2010; 28: 0-0. IF: 1.393

  • HIV infection in different age groups: Potential implications for prevention. CoRIS Cohort, Spain, 2004-2008

    Caro-Murillo AM, Luciano AG, Rubio GN, Noval ML, Ramos JRB
    MED CLIN-BARCELONA. 2010; 134: 521-527. IF: 1.231

Guies clíniques
  • Antiretroviral Treatment of Adult HIV Infection 2010 Recommendations of the International AIDS Society-USA Panel

    Thompson MA, Aberg JA, Cahn P, Montaner JSG, Rizzardini G, Telenti A, Gatell JM, Gunthard HF, Hammer SM, Hirsch MS, Jacobsen DM, Reiss P, Richman DD, Volberding PA, Yeni P, Schooley RT
    JAMA-J AM MED ASSOC. 2010; 304: 321-333. IF: 28.899

Tornar